This Amendment No. 2 to the Schedule 13G (“Amendment No. 2”) relating to Thorne Healthtech, Inc., a Delaware corporation (the “Issuer”), is being filed on behalf of the undersigned to amend the Schedule 13G filed with the Securities and Exchange Commission on February 10, 2023, as amended (the “Schedule 13G”). This Amendment No. 2 is the final amendment to the Schedule 13G and is an exit filing.
Thorne Healthtech, Inc.
| (b) | Address of Issuer’s Principal Executive Offices: |
152 W 57th Street, New York, NY 10019
| (a) | Name of Person Filing: |
Mitsui & Co., Ltd.
| (b) | Address of Principal Business Office or, if none, Residence |
2-1 Ohtemachi 1-Chome, Chiyoda-ku, Tokyo, 100-8631 JAPAN
Japan
| (d) | Title of Class of Securities: |
common stock, par value $0.01 per share
885260 109
Item 3. | If this statement is filed pursuant to §§240.13d-1(b), or 240.13d-2(b) or (c), check whether the person filing is a: |
Not Applicable.
The information required by Items 4(a)—(c) is set forth in Rows 5-9 and 11 of the cover page for the Reporting Person and is incorporated herein by reference.
On August 27, 2023, the Issuer entered into an Agreement and Plan of Merger with Healthspan Buyer, LLC and Healthspan Merger Sub, Inc. (“Purchaser”) pursuant to which Purchaser commenced a tender offer (the “Offer”) to purchase all of the issued and outstanding shares of common stock of the Issuer, $0.01 par value per share (the “Company Capital Stock”). Following the expiration time of the Offer, Purchaser accepted the Company Capital Stock validly tendered pursuant to the Offer at a purchase price of $10.20 per share in cash, without interest and subject to applicable withholding taxes. As a result, as of October 16, 2023, the Reporting Person is no longer the beneficial owner of any securities of the Issuer.